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South Africa (SA) is challenged with a 
quadruple burden of disease that reflects 
the complex nature of its population and 
healthcare delivery systems. These diseases 
include maternal, new-born and child 
health; HIV/AIDS and tuberculosis (TB); 
non-communicable  diseases; and violence 
and trauma.[1] The management of most 
of these diseases includes, at least in part, 
the use of blood and blood products, 
while future management will increasingly 
involve novel cellular therapeutic services 
and products.
The primary objective of blood 
transfusion services in SA is to supply safe, 
sufficient, quality blood products in an 
equitable manner to all patients in need. 
This mandate is met by the South African 
National Blood Service (SANBS), which 
supplies products to 8 of the 9 provinces, 
and the Western Cape Blood Service 
(WCBS), which supplies blood products to 
Western Cape Province.
In 2018, SANBS provided more than 
a million blood products to more than 
320  000 patients. SANBS has actively 
increased the size of the black donor panel 
(Fig. 1) as well as the number of units 
collected from these donors (Fig. 2). The 
main drivers of blood product use in SA 
include obstetric haemorrhage, treatment 
of a multitude of cytopaenias associated 
with diseases such as HIV,[2] TB and other 
medical conditions, and trauma and 
surgical emergencies (Table 1). This is in 
contrast to developed countries where most 
blood components are issued to elderly 
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Fig. 1. Distribution of active donor panel by ethnic group from 2010 to 2018.
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Fig. 2. Distribution of successful collections by ethnic group from 2010 to 2018.
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patients undergoing complex cardiovascular and orthopaedic 
surgery, those who have trauma or sepsis, and patients who require 
supportive therapy while being treated for malignancies.[3]
To meet the needs of these patients, the healthcare system requires 
a constant supply of safe blood products. Donation of blood in SA is 
on a voluntary, non-remunerated basis, therefore the blood supply is 
precarious and relies on the willingness of healthy people to donate 
regularly.
Currently, up to 20% of the SA donor population is deferred for 
various reasons, including various medical conditions and surgical 
interventions, exposures and behaviours placing potential donors 
at risk of transfusion transmissible infections as well as travel to 
malaria endemic areas (Table 2). However, the single biggest reason 
for deferral, accounting for almost 50% of deferrals, is donors 
presenting with low haemoglobin levels.[4] Ensuring a sufficient 
blood supply while maintaining donor health in general (and iron 
levels in particular) remains an ongoing challenge, especially in a 
country where the blood demand is increasing as access to healthcare 
in previously disadvantaged communities improves. In this review, 
we consider the current landscape and the future direction of this 
paradigm shift in SANBS.
The current landscape
Patient blood management
In response to both an increasing demand for blood products in 
developing countries and concerns regarding potential over-transfusion 
of patients in developed countries, the World Health Assembly 
recommended the implementation of patient blood management 
(PBM) to its member states in 2010.[5] PBM is an evidence-based 
bundle of care that optimises medical and surgical patient outcomes by 
clinically managing and preserving a patient’s blood.[6]
The three pillars of PBM address anaemia, bleeding and preserving 
the patient’s own blood. A programmatic approach to PBM has 
been associated with improved patient and economic outcomes and 
reduced transfusion rates.[6] Successful national adoption of PBM 
in SA will assist in addressing concerns around liberal transfusion 
practices in certain sectors of the healthcare system, while at the same 
time increasing availability of products in historically underserviced 
areas, such as district hospitals in deep rural areas.
Internationally, the underlying rationale for this patient-centric 
approach is simple and compelling: PBM is not only associated with 
better patient outcomes, but also with a reduction in healthcare 
expenditure.[6-8]
Consequently, the implementation of PBM is becoming more 
widespread and, where this occurs, blood transfusion services – 
especially in developed countries – are experiencing a significant 
decline in blood use.[9] In addition, new developments in the 
management of many diseases have created demand for new blood 
products and services. In response to this changing landscape, blood 
transfusion services are expanding their service and product offering, 
which may include therapeutic apheresis and cellular therapies.[10]
As we continue implementing PBM in the diverse and complex 
South African healthcare environment, our focus shifts from product 
to patient. This patient focus includes therapeutic apheresis and 
cellular therapies.
Therapeutic apheresis services
Therapeutic apheresis is a treatment modality that involves drawing a 
patient’s blood, separating and removing a targeted component, and 
retransfusing the remainder of the blood components into thepatient. 
Current evidence recommends it as part of first- or second-line 
treatment for a host of immunological disorders.[11]
SANBS has provided therapeutic apheresis services in the form of 
plasma exchange, leucopheresis, red cell exchange and haematopoietic 
progenitor stem cell collections since 1997.
The most common indication for therapeutic apheresis is plasma 
exchange for thrombotic thrombocytopenic purpura (TTP) in HIV-
positive patients.[12] TTP is a medical emergency that presents with a 
thrombotic microangiopathy and is associated with a 90% mortality 
rate if untreated.[13,14] From 2011 to 2018, SANBS performed 5  267 
plasma exchange procedures on 517 patients with TTP in 21 
hospitals. Most of these patients were HIV-positive (78%) and 
antiretroviral naive at the time of diagnosis. Two recent publications 
on the survival rate of TTP patients with HIV in South Africa treated 
with plasma exchange report survival rates of 70.7% and 96.5% 
respectively.[15,16] TTP may provide unique research opportunities 
into the effect of HIV on vascular biology generally, and on the 
endothelium specifically, through ADAMTS13 and Von Willebrand 
Factor (VWF) testing,[14] as well as next-generation sequencing, 
transcriptomics and proteomics.
Other less common indications for plasma exchange referred 
to SANBS include neuromyelitis optica, acute inflammatory 
demyelinating polyneuropathy, myasthenia gravis including 
myasthenic crisis, and antibody-mediated renal transplant rejection.
Cellular therapy services
Haematopoietic stem cell transplantation (HSCT) is a procedure 
where stem cells are collected from an autologous or allogeneic 
Table 1. Number of products issued by discipline during 2018
Discipline Products issued, n (%)
Burn units 3 834 (0.4)
Cardiothoracic surgery 23 762 (2.3)
General surgery 115 841 (11.3)
Obstetrics and gynaecology 173 087 (16.9)
Haematology/oncology 62 196 (6.1)
ICU 171 088 (16.7)
Infectious diseases 1 651 (0.2)
Medical 296 157 (28.9)
Orthopaedics 23 044 (2.2)
Other 30 055 (2.9)
Paediatric surgery 2 428 (0.2)
Paediatrics 46 842 (4.6)
Trauma 28 610 (2.8)
Unknown 45 599 (4.5)
Total, N 1 024 194
Table 2. Distribution of donor deferrals, 2018
Deferral type Deferrals 2018, n (%)
Haematocrit/haemoglobin 93 215 (43.2)
High-risk exposures 33 976 (15.8)
Malaria risk 5 269 (2.4)
Medical conditions/medication 60 785 (28.2)
Pregnancy 7 077 (3.3)
Surgery/trauma 14 196 (6.6)
Weight 1 039 (0.5)
Total, N 215 557
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donor, processed and, if required, stored. After the patient receives 
a conditioning regimen, which may include radiation or high-dose 
chemotherapy, the processed cells are returned via intravenous 
infusion to regenerate the injured bone marrow. This procedure is 
often lifesaving and performed mainly on patients suffering from 
haematological malignancies and bone marrow failure syndromes.[17] 
The services which SANBS provides for HSCT patients include 
haematopoietic stem cell collection by apheresis, cryopreservation and 
thawing of collected cells, and CD34+ enumeration by flow cytometry.
A review by Baldomero et al.[18] reported significant gaps in 
HSCT rates in the World Health Organization’s combined Eastern 
Mediterranean and African region. They noted that only 29 (or 
1.85%) of transplant teams globally were operating in this region, 
performing 2 332 (3.3%) of the 71 036 HSCTs performed worldwide 
between 2006 and 2013.[18] Although this figure represents a 90% 
increase in the number of procedures from 2006 to 2013, this remains 
the region with the lowest transplant rates.
In SA, much has changed since 2013: new centres in both the public 
and private sectors have opened in Bloemfontein, Port Elizabeth, 
Umhlanga and Polokwane. Alberts Cellular Therapy (ACT) in 
Pretoria became the first unit in Africa to obtain international 
accreditation. In addition, haplo-identical transplant programmes 
were started successfully at both ACT and Groote Schuur Hospital 
in Cape Town, which significantly increase access to donors, even 
though most of the centres do not provide comprehensive stem cell 
transplantation programmes.
From January 2013 to July 2018, 546 patients were referred to 
SANBS for haematopoietic stem cell apheresis (HPC-A) from 13 
hospitals in both the public and private sectors across 4 provinces 
(Gauteng, Free State, KwaZulu-Natal and Eastern Cape) (Table 3). The 
most common procedure performed was autologous transplantation 
(n=491/546; 89.9%) and the most common indication was multiple 
myeloma. To date, very few allogeneic stem cell transplants have 
been performed by the units supported by SANBS.
To date, the number of patients referred and the number of units 
referring patients to SANBS continues to grow annually, reflecting 
the growing SANBS footprint, and also the expansion of access to 
such services by an increasing proportion of the population.
SANBS has developed HSCT service capacity in a similar fashion to 
other national or regional blood transfusion services, such as Sanquin 
in the Netherlands, and, once accreditation by the Joint Accreditation 
Committee of the International Society for Cellular Therapy and the 
European Society for Blood and Marrow Transplantation (JACIE) is 
obtained in 2020, SANBS will match its peers internationally.
Translational research
Blood transfusion services need to constantly balance the country’s 
current need for a safe, sustainable and cost-efficient blood supply 
against the need to develop specialised services and products that will 
be required in the future to support new therapeutic interventions. 
Transfusion and cellular-related translational research has been at the 
forefront of balancing these sometimes competing needs.[19]
In SA, the implementation of individual donation nucleic acid 
amplification testing for HIV, hepatitis B (HBV) and hepatitis 
C (HCV) significantly altered blood collection practices, while 
simultaneously improving the safety of the country’s blood supply 
to be comparable to that of many developed countries.[20,21]
Similarly, advances in monoclonal antibody-based blood group 
serology and, more recently, molecular DNA-based blood group 
testing, have improved compatibility testing in general and, 
particularly, in obstetric and prenatal medicine. This technique is 
used to differentiate between certain D antigens, such as weak D 
and partial D subgroups, which determine the need for Rh-immune 
prophylaxis to minimise the risk of haemolytic disease of the fetus 
and newborn.[22]
New technologies, such as pathogen reduction (PR) treatment 
of platelets introduced in several developed countries, will address 
bacterial contamination – as well as emerging infectious risks – up 
to now the most common adverse events associated with platelet 
transfusion.[23] Implementation of PR technology in SA in future 
may help alleviate chronic platelet shortages by enabling the use 
of relatively more plentiful buffy-coat-derived platelet products for 
many indications where single-donor apheresis platelet products 
are currently recommended.
A less appreciated area is the role that blood transfusion services 
play in ongoing HIV cure research. The Fiebig stage classification 
of the HIV immune response was developed through the analysis 
of stored blood products of repeat blood donors who tested HIV-
positive on subsequent donations.[24]
This cutting-edge basis of molecular testing for HIV is currently 
being further refined through the development of assays to quantify 
replication-competent, non-induced proviruses in the latent 
reservoir in fully suppressed HIV-positive patients.[25] SANBS is 
actively involved in local HIV research through the National Heart, 
Lung and Blood Institute-funded REDS-III Management and 
Acute Treatment of HIV Study (MATHS).[26] This study enrolled 
41 participants with acute HIV infection and 28 participants with 
recently acquired HIV, initiated very early antiretroviral treatment 
(ART) and followed the participants’ progress for up to 3 years. The 
main aims of the study were to establish the size of the peripheral 
blood viral reservoir at initiation of ART and at defined time points 
during follow-up, and to conduct a ‘proof of concept’ study to show 
how blood donors identified as having acute HIV infection and 
recently acquired HIV infection can be successfully linked to care 
and enrolled in a follow-up study with a national footprint.
New but rapidly expanding fields in international transfusion 
and cellular translational research focus on the production of cell 
lineages for use in a multitude of settings. Of potential critical 
importance to blood transfusion is the production of functional 
mature red blood cells from embryonic stem cells.[27]
Future direction
Cellular therapies provide an alternative and/or adjunct treatment 
to bridge the current unmet clinical demand in a range of chronic 
disorders, from non-communicable diseases, such as diabetes, to 
infectious diseases, including TB and HIV, and a multitude of 
malignancies. Here, we highlight a number of these promising 
therapeutic possibilities. SANBS will continue to investigate the 
feasibility of providing these products, or at least determine how best 
to support services associated with them.
Mesenchymal stromal cells
Mesenchymal stromal cells (MSCs) represent a population of 
tissue-resident non-haematopoietic adult progenitor cells originally 
Table 3. Number of transplant units accessing the SANBS 
cellular therapy services, 2013 - 2017
Heathcare 
setting 2013 2014 2015 2016 2017
Public 3 2 4 6 6
Private 5 5 5 7 6
Total 8 7 9 13 12
SANBS = South African National Blood Service.
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identified in bone marrow and subsequently in a number of organs, 
including adipose tissue.[28]
These cells can easily be expanded from adipose tissue as they 
can be grown in tissue culture and have the capacity to differentiate 
into fat, cartilage and bone. When reinfused, they are believed to 
migrate to sites of injury and inflammation, promoting tissue repair. 
Numerous clinical trials are ongoing in bone and cartilage repair and 
other settings.[29]
MSCs have other unique qualities. Recent studies have shown 
significantly reduced insulin requirement in patients with type I 
diabetes after the administration of Wharton’s jelly-derived 
(umbilical-cord) MSCs.[30] Similar results were shown in an open-
label clinical trial after co-transplantation of adipose-derived MSCs 
and haematopoietic stem cells in the same population. In addition, 
MSCs dampen inflammation through an array of interactions with 
innate and adaptive immune cells, thereby modulating immune 
responses.[31]
An ongoing study in Durban, SA, is establishing the safety of adjuvant 
autologous MSC therapy in SA patients with multidrug-resistant or 
extreme multidrug-resistant TB. These patients, in particular, would 
benefit from immune modulation to prevent the tissue damage caused 
by the immune response to the TB microbe.[32] These are all promising 
research areas and SANBS is exploring the commercial production of 
MSCs and testing in clinical trials.
Natural killer cells
Natural killer (NK) cells play a critical role in viral immunity. In 
the HIV infection setting, epidemiological and functional evidence 
supports a role for NK cells in both protection from infection 
acquisition as well as in viral control.[33]
NK cells directly mediate immune pressure leading to virus 
evolution, and NK cell receptor genotypic profiles, clonal repertoires 
and functional capacity have all been implicated in virus containment. 
In addition, indirect NK cell-mediated antibody-dependent cellular 
cytotoxicity has been linked to vaccine-induced protective immunity 
against HIV infection.
With recent advances in the understanding of NK cell deficiency, 
development, memory-like responses and editing of the adaptive 
immune system, the opportunities to direct and exploit NK cell 
antiviral immunity to target HIV have grown exponentially.[34] To this 
point, a recent publication on a SA cohort study by Ramsuran et al.[35] 
confirms the hypothesis that NK cell function is linked to HLA-A 
overexpression, which may lead to rapid progression in a subset of 
HIV-positive patients in SA.[35]
One possibility to address NK cell dysfunction will be to transfer 
NK cells with different functionality from genotypically different 
donors, an example of adoptive immunotherapy in the treatment 
of HIV. SANBS endeavours to collaborate with other researchers in 
this field to create the pathway for the delivery of potential adoptive 
therapies to the patient.
Chimeric antigen receptor T cells
The various eras of treatment of malignancies are marked by 
increasing tumour specificity. In 2018, the first chimeric antigen 
receptor T cell (CART) products (axicabtagene ciloleucel and 
tisagenlecleucel) were approved for clinical use, heralding the dawn 
of immune therapies for certain B cell leukaemias and lymphomas.[36]
Chimeric antigen receptors are receptor proteins that have been 
engineered to give T cells a new ability to target a tumour neoantigen. 
The chimeric nature of these receptors stems from the combined 
antigen-binding and T cell-activating functions in a single receptor. 
These genetically modified cytotoxic T cells have the ability to target 
not only tumour cells, but also cells infected by viruses. Consequently, 
the first T cells against HIV infection have already been produced and 
are being tested in clinical trials.[37]
This field is rapidly expanding: by October 2018, 322 ‘chimeric 
antigen receptor’ clinical trials (128 recruiting in the USA and 158 
in China) were registered on clinicaltrials.gov, covering a range 
of indications, including haematological malignancies, solid-organ 
tumours, and autoimmune and infectious diseases.
These data are compared to fewer than 10 such trials registered in 
September 2010, 77 in September 2015, and 144 in September 2016. 
The probability of breakthrough treatments for targeted diseases has 
increased significantly, and the SA healthcare system will have to 
prepare for this new treatment modality. SANBS can play a critical 
role in the harvesting, production and quality assurance of CART 
cells, and aims to collaborate with and assist the South African Stem 
Cell Transplantation Society with future platforms to ensure the SA 
public has access to such therapies.
Production of red blood cells
Recent advances in stem cell culturing techniques have seen an 
increase in approaches aimed at manufacturing red blood cells and 
platelets ex vivo. In SA, this development will address the risk of 
decreasing blood donor pools compounded by an ageing donor 
population and a growing national blood demand, as well as blood 
safety issues posed by the current HIV epidemic and emerging 
pathogens, all of which are predicted to be a threat to blood supply 
in SA.[27]
The UK’s National Health Service has been one of the first services 
to take up the challenge to produce red cell products grown ex 
vivo. Although there are infrastructural, technological and financial 
challenges, these will most likely be overcome as technology becomes 
faster, better and cheaper, making the production of blood products 
ex vivo in a financially sustainable manner feasible in the medium 
term.
Next steps
When one considers the history of blood services, from the first 
transfusion of non-tested blood products in 1 625 to the quality and 
blood safety standards of today, it is no surprise that blood services 
are at the forefront of implementing new technologies and products 
to improve patient outcomes. New technologies aimed at producing 
MSCs, NK cells and CART cell products show real promise, and 
should be pursued as a new pillar of therapeutic options to alleviate 
the burden of disease in SA. SANBS aims to contribute to this field in 
a step-by-step manner.
Firstly, we are focused on obtaining an appropriate international 
accreditation standard (JACIE) by 2020. Secondly, we will establish 
a translational research office in collaboration with our local and 
international experts, with a clearly defined research agenda that 
includes novel therapies and products. Thirdly, we will establish a 
production plant which will produce products such as human platelet 
lysate (a stem-cell growth medium) and MSCs, as the forerunners of 
more advanced cell products.
Finally, SANBS will also work towards meeting advanced therapy 
medicinal products (ATMP) standards and regulatory approval. The 
Official Journal of the European Union defines ATMP as either one 
or a combination of gene-therapy medicinal products, somatic cell 
therapy medicinal products or tissue-engineered products.[38]
The proposed South African National Health Insurance Bill 
necessitates the careful consideration and appropriate use of both 
health products and services with a clear focus on sustainability 
within the resource-constrained environment of the SA healthcare 
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environment. Ongoing research suggests that access to curative 
procedures and products may be cost effective when it increases 
the probability of cure and reduces the need for further lines of 
therapy. This dynamic is seen when performing an allogeneic 
stem cell transplant early in the course of high-risk leukaemia and 
may be proven in cellular therapies such as CART cells in B-acute 
lymphoblastic leukaemia.[39] Towards this end, SANBS will continue 
to support best-practice, evidence-based transfusion services and 
pursue close collaboration with bodies such as the South African 
Centre for Epidemiological Modelling and Analysis, the South 
African Health Products Regulatory Authority, and the Department 
of Health to ensure improved population-based health outcomes and 
sustainability.
Conclusion
As we consider the future of blood transfusion, it is evident that PBM 
and rapid changes in the management of diseases will force services 
to reinvent themselves. SANBS will do so by expanding into the field 
of therapeutic apheresis and cellular therapies in order to offer a 
much-needed new therapeutic pillar that may offer cures for many 
who suffer from infectious and malignant diseases.
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